Immune reconstitution of B‐cell lymphoma patients receiving CHOP‐based chemotherapy containing rituximab
- 7 March 2011
- journal article
- research article
- Published by Wiley in Hematological Oncology
- Vol. 29 (1) , 5-9
Abstract
Sixty‐six B‐cell lymphoma patients were treated with a CHOP‐based chemotherapy containing rituximab (R‐CHOP‐like regimen). Immune reconstitution was assessed by measuring lymphocyte subsets and immunoglobulins. Fifty‐five patients (83.3%) underwent six cycles of the R‐CHOP‐like regimen. CD19+ and CD20+ cells were completely eliminated from the peripheral blood after one cycle of the R‐CHOP‐like regimen; they were detected again 6 months after the therapy. One year after the therapy, B‐cell numbers recovered to their level at diagnosis and almost doubled 2 years after the therapy. The lowest numbers of CD3+, CD8+ and CD56+ cells were seen after three cycles of the regimen, but continued to increase until 1 year after the therapy, remaining stable thereafter. CD4+ T‐cells were at their lowest after six cycles of the regimen and recovered slowly for 2 years after the therapy; however, their numbers were still lower than that at diagnosis. Immunoglobulins decreased over six cycles of the R‐CHOP‐like regimen and then recovered gradually for 2 years after the therapy. The percentage of IgG, IgA and IgM 2 years after the therapy compared with those at diagnosis was 93.9%, 90.1%, 76.3%, respectively. Twelve infectious complications occurred which consisted of three febrile neutropenia, three Herpes Zoster, two tympanitis, two Pneumocystis jiroveci pneumonia and two hepatitis B virus reactivation. B‐cells required 1 year and CD4+ T‐cells and immunoglobulins needed 2 years to recover after the therapy. Copyright © 2010 John Wiley & Sons, Ltd.Keywords
This publication has 22 references indexed in Scilit:
- Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphomaAnnals of Oncology, 2009
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without RituximabJournal of Clinical Oncology, 2009
- Retrospective Analysis of Intravascular Large B-Cell Lymphoma Treated With Rituximab-Containing Chemotherapy As Reported by the IVL Study Group in JapanJournal of Clinical Oncology, 2008
- Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopeniasPediatric Blood & Cancer, 2007
- Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphomaBone Marrow Transplantation, 2006
- Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood, 2005
- Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK)Journal of Clinical Oncology, 2005
- Immune Recovery of Lymphocyte Subsets 6 Years after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) for Lymphoproliferative Diseases. A Comparison between NHL, HD and MM in Group of 149 PatientsLeukemia & Lymphoma, 2004
- Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphomaBlood, 2004
- Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphomaCancer, 1976